Clinical Outcome Assessment (COA)

A clinical outcome assessment (COA) is any measure that describes or reflects how a clinical trial participant feels, functions, or survives — the FDA’s own definitional test for the category. A measure only counts as a COA if it is reported by a clinician, the patient, a non-clinician observer, or captured through a standardized performance task; a laboratory value, imaging result, or other physiological measurement is not a COA even when it correlates with how a patient is doing (see COA vs. biomarker below).

The four COA types

FDA’s Center for Drug Evaluation and Research (CDER) and the FDA-NIH BEST (Biomarkers, EndpointS, and other Tools) Resource define exactly four COA categories, distinguished by who generates the report:

• Patient-Reported Outcome (PRO) — a measurement based on a report that comes directly from the patient about their own health status, “without amendment or interpretation of the patient’s response by a clinician or anyone else.” Captured through questionnaires, numeric rating scales, or diaries.
• Clinician-Reported Outcome (ClinRO) — a measurement based on a report from a trained health-care professional after observing the patient, used when clinical judgment is required to interpret a sign or rate its severity.
• Observer-Reported Outcome (ObsRO) — a measurement based on a report of observable signs, events, or behaviors by someone who is neither the patient nor a health professional — typically a parent or caregiver reporting on a patient who cannot reliably self-report (e.g., an infant or a person with advanced dementia).
• Performance Outcome (PerfO) — a measurement based on a standardized task the patient actively performs according to a set instruction, such as a timed walk test or a reading-speed test, scored by a trained assessor rather than self-reported.

Why COAs matter for regulatory approval

COAs are the mechanism FDA uses to evaluate whether a drug, biologic, or device produces a benefit patients can actually perceive — as opposed to a benefit that shows up only in a laboratory value. A trial’s primary or key secondary endpoint is frequently built directly from a COA instrument (for example, change from baseline on a validated PRO questionnaire). Because the instrument itself becomes part of the regulatory evidence, FDA cares not just that an outcome was measured, but that it was measured with a COA that is well-defined and reliable for the specific concept of interest and context of use in that trial — an unvalidated or ad hoc questionnaire is a common source of review deficiencies. FDA’s Patient-Focused Drug Development (PFDD) guidance series (four guidances, finalized/issued 2020–2023) sets out how sponsors should select, develop, or modify a COA to be fit for purpose in a given development program.

COA vs. biomarker vs. surrogate endpoint

These three terms are frequently conflated but describe different things in FDA’s own BEST Resource glossary:

• A biomarker is “a defined characteristic that is measured as an indicator of normal biological processes, pathogenic processes, or biological responses to an exposure or intervention” — a lab value, imaging finding, physiological measurement, or genetic marker. It is not a COA because it doesn’t itself describe how a patient feels, functions, or survives.
• A surrogate endpoint is “an endpoint used in clinical trials as a substitute for a direct measure of how a patient feels, functions, or survives.” Surrogate endpoints are usually built from a biomarker (e.g., LDL cholesterol as a surrogate for cardiovascular events, viral load as a surrogate for HIV disease progression). FDA distinguishes a validated surrogate endpoint (strong mechanistic and clinical evidence it predicts clinical benefit, usable to support approval without further outcome data) from a reasonably likely surrogate endpoint (weaker evidence, typically supports only accelerated approval pending confirmatory data).
• A COA-based endpoint, by contrast, IS a direct measure of clinical benefit — there’s no substitution step, which is why regulators generally treat COA-based endpoints as stronger evidence of a drug’s real-world benefit than a surrogate endpoint alone.

In practice, a single pivotal trial often combines both: a survival or biomarker-based endpoint alongside a COA to show the treatment also makes patients feel or function better, not just that a lab value moved.

The COA Qualification Program

Because building and validating a COA instrument from scratch is expensive and time-consuming, FDA runs a voluntary COA Qualification Program under its broader Drug Development Tools framework. A “qualified” COA is a regulatory conclusion that the instrument reliably measures a specified concept of interest within a specified context of use; once qualified, any sponsor can rely on it for that context without re-justifying its suitability to FDA each time. Sponsors are not required to use a qualified COA — a non-qualified, but still well-justified, fit-for-purpose COA can support a trial endpoint too.

Related CASRAI terms

• Clinical Trial Registration
• IRB (Institutional Review Board)
• What Is a Clinical Trial? The NIH Definition Explained
• Clinical Trial Registration and Reporting Compliance
• IRB/REC Approval Process
• Clinical Research Administration (cluster overview)

References

• FDA, Clinical Outcome Assessment (COA): Frequently Asked Questions — fda.gov/about-fda/clinical-outcome-assessment-coa-frequently-asked-questions
• FDA, Patient-Focused Drug Development Glossary — fda.gov/drugs/development-approval-process-drugs/patient-focused-drug-development-glossary
• FDA-NIH, BEST (Biomarkers, EndpointS, and other Tools) Resource, Glossary — ncbi.nlm.nih.gov/books/NBK338448/
• FDA, Clinical Outcome Assessment (COA) Qualification Program — fda.gov/drugs/drug-development-tool-ddt-qualification-programs/clinical-outcome-assessment-coa-qualification-program
• FDA, Surrogate Endpoint Resources for Drug and Biologic Development — fda.gov/drugs/development-resources/surrogate-endpoint-resources-drug-and-biologic-development